A small feasibility study of a new containment bag for power morcellation shows that it may be reliable for even a large specimen. The findings, about the Espiner EcoSac 230, were presented at the 45th AAGL Global Congress in Orlando, Florida.
A small feasibility study of a new containment bag for power morcellation shows that it may be reliable for even a large specimen. The findings, about the Espiner EcoSac 230, were presented at the 45th AAGL Global Congress in Orlando, Florida.
The research involved 187 procedures performed at 3 independent hospitals in Illinois between May 2014 and December 2015. All of the patients underwent contained electromechanical power morcellation during a laparoscopic or robotic-assisted hysterectomy or myomectomy. Three physicians performed the surgeries using the Espiner EcoSac 230 specimen bag.
The average specimen weight was 300 g and the largest was 2,134 g. Mean patient age was 40 (range 25-54 years) and mean body mass index was 28.7 (range 17.3-57.6) Nearly three quarters of the surgeries were myomectomies (73.8%) and just over one quarter were hysterectomies (26.2%) The mean number of fibroids removed during the myomectomies was 4.9 and mean estimated blood loss was 98.4 mL.
The postoperative admission rate was 12.3%, the majority because of nausea and urinary retention. Only 20 patients (10.7%) had postoperative complications, most of which the authors said were minor, and 4 patients (2.1%) were readmitted.
Commenting on the specimen bag, the authors said it was a “feasible, reliable, and reproducible method of contained power morcellation, even for a large specimen.”
Steller CJ, Miller CE, Sasaki KJ, et al. Review and outcome of electromechanical power morcellation using an innovative contained specimen bag system. Abstract 128. JMIG 2016;23(7):S53.
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More